- Home
- VYNE vs DTIL Comparison
VYNE vs DTIL Comparison
Compare VYNE & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- DTIL
- Stock Information
- Founded
- VYNE 2003
- DTIL 2006
- Country
- VYNE United States
- DTIL United States
- Employees
- VYNE N/A
- DTIL N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- DTIL Health Care
- Exchange
- VYNE Nasdaq
- DTIL Nasdaq
- Market Cap
- VYNE 41.9M
- DTIL 44.1M
- IPO Year
- VYNE 2018
- DTIL 2019
- Fundamental
- Price
- VYNE $2.32
- DTIL $4.96
- Analyst Decision
- VYNE Strong Buy
- DTIL Strong Buy
- Analyst Count
- VYNE 2
- DTIL 3
- Target Price
- VYNE $6.88
- DTIL $37.67
- AVG Volume (30 Days)
- VYNE 129.4K
- DTIL 1.2M
- Earning Date
- VYNE 02-27-2025
- DTIL 03-26-2025
- Dividend Yield
- VYNE N/A
- DTIL N/A
- EPS Growth
- VYNE N/A
- DTIL N/A
- EPS
- VYNE N/A
- DTIL 1.45
- Revenue
- VYNE $493,000.00
- DTIL $75,096,000.00
- Revenue This Year
- VYNE $28.30
- DTIL $51.35
- Revenue Next Year
- VYNE N/A
- DTIL N/A
- P/E Ratio
- VYNE N/A
- DTIL $3.43
- Revenue Growth
- VYNE 39.27
- DTIL 43.62
- 52 Week Low
- VYNE $1.57
- DTIL $3.61
- 52 Week High
- VYNE $4.30
- DTIL $19.43
- Technical
- Relative Strength Index (RSI)
- VYNE 36.13
- DTIL 43.61
- Support Level
- VYNE $2.34
- DTIL $4.83
- Resistance Level
- VYNE $3.00
- DTIL $5.41
- Average True Range (ATR)
- VYNE 0.27
- DTIL 0.41
- MACD
- VYNE -0.08
- DTIL 0.04
- Stochastic Oscillator
- VYNE 8.24
- DTIL 13.08
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.